Lack of Association between Statin Use and Angiographic and Clinical Outcomes after Pipeline Embolization for Intracranial Aneurysms

Article Figures & Data

Table 1:

Baseline demographics and aneurysm characteristics

Subject Characteristics	Statin Use	No Statin Use	P Value
Age (yr)			<.001
Mean ± SD (No.)	64.6 ± 9.6 (225)	55.5 ± 14.0 (863)
Median (range)	65.0 (39.0–85.0)	56.0 (3.0–89.0)
Sex			.251
Male	15.9% (36/226)	19.4% (168/866)
Female	84.1% (190/226)	80.6% (698/866)
Hypertension
Yes	75.5% (123/163)	41.1% (289/703)	<.001
Controlled	91.3% (95/104)	83.5% (207/248)	.065
Not controlled	22.1% (36/163)	53.8% (378/703)	.065
No. of aneurysms	265	956
Aneurysm size (mm)			.716
Mean ± SD (No.)	11.6 ± 7.0 (261)	12.1 ± 8.0 (950)
Median (range)	10.2 (1.5–32.6)	10.2 (0.9–55.0)
Aneurysm neck (mm)			.868
Mean ± SD (No.)	6.6 ± 4.9 (231)	6.6 ± 4.8 (891)
Median (range)	5.6 (0.6–53.0)	5.3, (0.0–50.0)
Aneurysm size			.385
Small	36.4% (95/261)	39.9% (379/950)
Large	54.8% (143/261)	50.0% (475/950)
Giant	8.8% (23/261)	10.1% (96/950)
Aneurysm type			.001
Saccular	70.9% (188/265)	76.3% (729/956)
Fusiform	20.8% (55/265)	14.9% (142/956)
Dissecting	1.9% (5/265)	5.8% (55/956)
Other	6.4% (17/265)	3.1% (30/956)
Aneurysm location			.208
Internal carotid artery	81.9% (217/265)	79.5% (760/956)
Middle cerebral artery	2.6% (7/265)	4.1% (39/956)
Posterior cerebral artery	0.0% (0/265)	1.7% (16/956)
Basilar artery	4.5% (12/265)	4.0% (38/956)
Other	10.9% (29/265)	10.8% (103/956)
Presented with ruptured aneurysm	4.5% (12/265)	6.7% (64/956)	.197
Multiple PEDs used	43.9% (116/264)	35.2% (336/954)	.009

Table 2:

Angiographic outcomes (PUFS and ASPIRe only)^{^a}

Follow-Up	Statin Use	No Statin Use	P Value
Complete occlusion at 180 days (−20/+42 days)	84.8% (28/33)	72.2% (83/115)	.174
Complete occlusion at 1 year (±42 days)	82.8% (24/29)	86.4% (70/81)	.759
Complete occlusion at 3 years	94.7% (18/19)	93.0% (53/57)	1.000
Complete occlusion at 5 years	93.3% (14/15)	95.7% (45/47)	1.000
Complete occlusion at last follow-up visit	76.4% (42/55)	83.8% (129/154)	.227

Table 3:

Clinical outcomes^{^a}

Major Complication	Statin Use	No Statin Use	P Value
Major ipsilateral ischemic stroke	4.9% (11/226)	3.4% (29/865)	.319
Major ipsilateral intracranial hemorrhage	0.9% (2/226)	2.3% (20/865)	.284
Major morbidity	5.8% (13/226)	5.7% (49/865)	1.000
Neurologic mortality	3.5% (8/226)	3.2% (28/865)	.835
Major morbidity and neurologic mortality	7.5% (17/226)	7.1% (61/865)	.773
All-cause mortality	4.4% (10/226)	3.9% (34/865)	.706

Table 4:

Multivariable logistic regression analysis

Outcome: Major Complications	OR (Statin vs No Statin)	95% Lower Bound	95% Upper Bound	P Value
All-cause mortality	0.72	0.34	1.53	.397
Major ipsilateral intracranial hemorrhage	0.31	0.09	1.14	.078
Major ipsilateral ischemic stroke	1.43	0.66	3.09	.362
Major morbidity	0.83	0.42	1.64	.593
Major morbidity and neurologic mortality	0.80	0.44	1.47	.478
Neurologic mortality	0.65	0.28	1.47	.298
Stenosis >50% at last follow-up	2.83	0.53	15.09	.224
Without complete aneurysm occlusion at last follow-up	1.20	0.54	2.66	.657